The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

Dua K 1 , Wadhwa R 2 , Singhvi G 3 , Rapalli V 3 , Shukla SD 4 , Shastri MD 5 Show all authors , Gupta G 6 , Satija S 7 , Mehta M 7 , Khurana N 7 , Awasthi R 8 , Maurya PK 9 , Thangavelu L 10 , S R 10 , Tambuwala MM 11 , Collet T 12 , Hansbro PM 13 , Chellappan DK 14

Affiliations 

  • 1 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales, Australia
  • 2 Faculty of Life Sciences and Biotechnology, South Asian University, New Delhi, India
  • 3 Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani, India
  • 4 Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) and School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia
  • 5 School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Australia
  • 6 School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India
  • 7 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
  • 8 Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India
  • 9 Department of Biochemistry, Central University of Haryana, Mahendergarh, Haryana, India
  • 10 Nanobiomedicine Lab, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India
  • 11 School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, London, United Kingdom of Great Britain and Northern Ireland
  • 12 Inovative Medicines Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
  • 13 Centenary Institute, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
  • 14 Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
Drug Dev Res, 2019 09;80(6):714-730.
PMID: 31691339 DOI: 10.1002/ddr.21571

Abstract

Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency, and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers, which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications